Drug delivery development deal for Bespak:
This article was originally published in Clinica
The developer of drug delivery technologies, Bespak (Milton Keynes), has agreed to collaborate with fellow UK company, Innovata Biomed (IB), the respiratory division of ML Laboratories, on the development of IB's C200 multi-dose dry powder inhaler device, used to deliver combination drug therapies for diseases such as asthma. Bespak will manufacture the devices on a pilot scale as required for the clinical trial of the therapy. According to ML Laboratories, IB has already found a European distributor - whose name was not disclosed - for the C200 inhaler, following "a multi-million pound licensing agreement".
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.